India  

DGCI gives nod for Covaxin Phase II/III trials on 2-18 year olds

IndiaTimes Thursday, 13 May 2021
The Indian drugs regulator, the Drugs Controller General of India (DCGI) has granted its approval to indigenously developed Covid-19 vaccine Covaxin’s developer Bharat Biotech for conducting Phase II/III clinical trials of the desi vaccine on children from 2 to 18 years of age. The children’s trials will be carried out on 525 healthy children volunteers with two doses.
0
shares
ShareTweetSavePostSend
 

💡 newsR Knowledge: Other News Mentions

Drugs Controller General of India Drugs Controller General of India

Gautam Gambhir Foundation guilty of hoarding FabiFlu Covid vaccine: DGCA| Delhi HC | Oneindia News [Video]

Gautam Gambhir Foundation guilty of hoarding FabiFlu Covid vaccine: DGCA| Delhi HC | Oneindia News

The Drugs Controller General of India has found the Gautam Gambhir Foundation guilty of stocking, procuring and distributing Fabiflu medicine in an unaurthorised manner to the COVID-19 patients, the Delhi High Court was informed on Thursday. #GautamGambhir #DCGA #FabiFlu

Credit: Oneindia    Duration: 01:45Published
Pfizer and Moderna vaccines may arrive in India soon| DCGI paves the way | Oneindia News [Video]

Pfizer and Moderna vaccines may arrive in India soon| DCGI paves the way | Oneindia News

In a move to pave the way for the availability of vaccines like Pfizer and Moderna in India, the Drugs Controller General of India (DCGI) has exempted foreign Covid-19 vaccines approved by specific nations or health bodies from post-approval bridging trials in the country. #Pfizer #Moderna #Covid19Vaccine

Credit: Oneindia    Duration: 02:05Published
Covid update: Decongesting jails; DRDO's new oral drug; task force for oxygen [Video]

Covid update: Decongesting jails; DRDO's new oral drug; task force for oxygen

From DCGI approving new anti-Covid drug, to health ministry issues new rules for hospital admissions, here are the top updates on the coronavirus. DCGI approved a new anti-Covid oral drug, which has been developed by DRDO and Dr. Reddy’s. The medicine has been given emergency use approval by DCGI. Meanwhile, Health Ministry said that a positive Covid-19 report is now not mandatory for a patient to be admitted to a hospital. Also, Supreme Court formed a 12-member National Task Force on medical oxygen. The new panel includes 10 doctors and 2 top bureaucrats from the Centre, who will ensure streamlined delivery of oxygen across India. Watch the full video for more updates on the pandemic.

Credit: HT Digital Content    Duration: 03:24Published
DCGI approves DRDO's anti-COVID drug helpful in faster recovery [Video]

DCGI approves DRDO's anti-COVID drug helpful in faster recovery

Drugs Controller General of India (DCGI) on May 08 approved emergency use DRDO's anti-COVID drug which the agency said will be helpful in faster recovery of hospitalised patients. While speaking to ANI, Institute of Nuclear Medicine and Allied Sciences (INMAS-DRDO) scientists spoken about drug 2-deoxy-D-glucose (2-DG). The drug will be of immense benefit to the people suffering from COVID-19.

Credit: ANI    Duration: 02:44Published

Covaxin Covaxin Vaccine against COVID-19

Covid-19: WHO accepts expression of interest for Covaxin emergency use listing

Covaxin has inched a step closer to a World Health Organization (WHO) emergency use listing (EUL) with the global body accepting Bharat Biotech’s expression of..
IndiaTimes

WHO accepts Bharat Biotech's Expression of Interest for Covaxin emergency use listing

The World Health Organisation (WHO) has accepted Bharat Biotech’s expression of interest (EoI) for the emergency use listing (EUL) of India's first..
IndiaTimes

Bharat Biotech, WHO pre-submission meeting on June 23: WHO

Hyderabad-based Bharat Biotech's pre-submission meeting has been scheduled on June 23 for evaluation of the World Health Organisation (WHO)'s Emergency Use..
IndiaTimes
New born calf serum in Covaxin? Health Ministry corrects facts | Oneindia News [Video]

New born calf serum in Covaxin? Health Ministry corrects facts | Oneindia News

Several social media users including Congress members have been sharing an RTI report that details the "ingredients" used in the India-made Covid-19 vaccine. #Covaxin #CalfSerum #FactCheck

Credit: Oneindia    Duration: 02:00Published

COVID-19 COVID-19 Disease caused by severe acute respiratory syndrome coronavirus 2

'He has been brave': UK's longest-known COVID patient dies after withdrawing from treatment

The UK's longest-known coronavirus patient has died after choosing to withdraw from treatment, his wife has confirmed.
Sky News
CNN Heroes: Helping the homeless through the pandemic [Video]

CNN Heroes: Helping the homeless through the pandemic

The Covid-19 could not stop CNN Hero Shirley Raines from serving the homeless on Skid Row, but it did force her to make some changes.

Credit: Bleacher Report AOL    Duration: 01:33Published

Cinderella not going to the ball as Lloyd Webber withdraws musical from live events COVID pilot

Andrew Lloyd Webber has pulled his latest musical out of a government pilot scheme for live events because theatre had been treated as "an afterthought and..
Sky News
Slavitt: Covid-19 a manageable challenge for kids [Video]

Slavitt: Covid-19 a manageable challenge for kids

Andy Slavitt, former White House Senior Adviser for Covid and author of “Preventable”, talks about the Delta variant, vaccinations and Obamacare.

Credit: Bleacher Report AOL    Duration: 14:31Published

Bharat Biotech Bharat Biotech Indian biotechnology company and vaccine manufacturer

Fact Check: No newborn calf serum in Covaxin, Health Ministry and Bharat Biotech confirm

The final vaccine does not contain newborn calf serum at all as the calf serum is not an ingredient of the final vaccine product, Health Ministry said
DNA

You Might Like


Related videos from verified sources

Covid-19: Aiims Delhi to begin Covaxin clinical trials for Children from today | Oneindia News [Video]

Covid-19: Aiims Delhi to begin Covaxin clinical trials for Children from today | Oneindia News

The screening of children for clinical trials of Covaxin will start at AIIMS in Delhi from today, days after similar trials started at AIIMS in Patna. AIIMS Delhi will conduct clinical trials of the..

Credit: Oneindia     Duration: 01:24Published

Related news from verified sources

Hyderabad: Bharat Biotech in talks with global MNCs to make Covaxin

After sealing a deal with Indian Immunologicals Ltd (IIL) for manufacturing its indigenous Covid-19 vaccine Covaxin, Bharat Biotech is now in parleys with global...
IndiaTimes Also reported by •Zee News

At Rs 700-Rs 1,500, price of Covid vaccine in India’s private sector among costliest

From Rs 250, the cost of vaccines in the private sector has shot up by up to six times. It now ranges from Rs 700-900 for Covishield manufactured by the Serum...
IndiaTimes

Bharat Biotech to ramp up Covaxin production to 1 billion doses a year

Hyderabad-based Bharat Biotech is planning to scale up the production capacity of its indigenously-developed Covid vaccine — Covaxin — to 1 billion doses per...
IndiaTimes Also reported by •Zee NewsDNA